# A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

> **NCT01284920** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 47 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Neoplasms
- Castration Resistant Prostate Cancer (CRPC)

## Interventions

- **DRUG:** MDV3100

## Key facts

- **NCT ID:** NCT01284920
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-02
- **Primary completion:** 2012-07-12
- **Final completion:** 2014-07-02
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2024-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01284920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01284920, "A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01284920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*